SCHEMBL4258714

SCHEMBL4258714

CC(=O)N1CCC2(CC1)CN(Cc1ccccc1F)C(=O)O2

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RIPK1 Q13546 1/20 0.48
MEN1 O00255 1/20 0.47
RAB9A P51151 1/20 0.47
KMT2A Q03164 1/20 0.47
ALDH1A1 P00352 4/20 0.45
CYP2D6 P10635 4/20 0.45
CYP2C19 P33261 2/20 0.45
KDM4E B2RXH2 2/20 0.45
POLB P06746 2/20 0.45
MAPT P10636 2/20 0.45
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
KDM1A O60341 1/20 0.42
SIGMAR1 Q99720 2/20 0.41
OPRM1 P35372 1/20 0.41
KCNH2 Q12809 1/20 0.41
MAPK1 P28482 1/20 0.41
TSHR P16473 2/20 0.41
SIRT2 Q8IXJ6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1085767 0.90 RIPK1 (0.52) RIPK1MEN1RAB9AKMT2AALDH1A1
SCHEMBL1086418 0.89 RIPK1 (0.48) RIPK1ALDH1A1CYP2D6CYP2C19KDM4E
SCHEMBL1086419 0.86 RIPK1 (0.48) RIPK1ALDH1A1CYP2D6CYP2C19KDM4E
SCHEMBL1085734 0.83 RIPK1 (0.48) RIPK1MEN1KMT2AALDH1A1CYP2D6
SCHEMBL1086096 0.83 RIPK1 (0.44) RIPK1ALDH1A1CYP2D6CYP2C19KDM4E
SCHEMBL1086117 0.83 RIPK1 (0.42) RIPK1MEN1KMT2AALDH1A1CYP2D6
SCHEMBL1086967 0.83 RIPK1 (0.46) RIPK1MEN1KMT2AALDH1A1CYP2D6
SCHEMBL1086248 0.82 RIPK1 (0.55) RIPK1MEN1KMT2AALDH1A1CYP2D6
SCHEMBL1086206 0.82 RIPK1 (0.48) RIPK1ALDH1A1CYP2D6CYP2C19KDM4E
SCHEMBL1086693 0.81 GRM5 (0.47) RIPK1ALDH1A1TACR2TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910381-B1 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2009-06-03 EP claimed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US claimed
EP-1910381-A2 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2008-04-16 EP claimed
WO-2007000325-A2 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2007-01-04 WO claimed
EP-1910381-B1 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS GRUENENTHAL GMBH (DE) 2009-06-03 EP disclosed
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs GRUENENTHAL GMBH (DE) 2009-04-23 US disclosed
EP-1910381-A2 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2008-04-16 EP disclosed
WO-2007000325-A2 SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS Grünenthal GmbH (DE) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105290-A1 Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs DDO, DAO, OTC RIPK1 3721/4885MEN1 1008/4885RAB9A 4568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.